A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder

Trial Profile

A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Sirukumab (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Oct 2016 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
    • 18 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top